Literature DB >> 23319093

Pharmacotherapy of Hospitalised HIV-Infected Patients in a General Hospital during 1990, 1997 and 2001.

Monique M R de Maat1, Teun M Post, Daniël M Jonker, Jan W Mulder, Pieter L Meenhorst, Eric C M van Gorp, Cornelis H W Koks, Anthonius de Boer, Jos H Beijnen.   

Abstract

OBJECTIVE: To describe the changes over time in drug therapy (antiretroviral as well as co-administered drugs) in HIV-infected patients who required hospitalisation during the period 1990-2001. In addition, we wanted to evaluate and compare the characteristics of these patients. DESIGN/
SETTING: Retrospective review of hospitalisations of HIV-infected patients in a general hospital.
RESULTS: During specified periods in 1990, 1997 and 2001, 22 patients out of 130 outpatients, 29 out of 394 outpatients, and 19 out of 570 outpatients, respectively, who were treated at the outpatient clinic were admitted 30, 38 and 27 times, respectively. The mean duration of these hospitalisations was 18.8, 14.2 and 16.7 days, respectively. The percentage of women and the mean age of the hospitalised patients increased over the studied time period. AIDS-related diagnoses decreased when comparing 1997 with 2001. The type of co-administered drugs of patients who required hospitalisation was fairly stable, but the total volume (defined as the mean volume of drugs per patient per bed-day) increased dramatically from 5.3 in 1990 to 6.8 in 1997 and to 15.5 in 2001. Dual and triple antiretroviral therapy decreased and became quadruple or greater therapy when 1997 and 2001 were compared. In addition, the number of hospitalised patients not treated with antiretroviral drugs increased from 1997 to 2001.
CONCLUSION: The incidence of hospital admissions decreased but the volume of co-administered drugs increased from 1990 to 2001, suggesting extensive co-morbidity in the patients who still require hospitalisation.

Entities:  

Year:  2003        PMID: 23319093     DOI: 10.2165/00044011-200323010-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  11 in total

1.  Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA.

Authors:  Y Mouton; S Alfandari; M Valette; F Cartier; P Dellamonica; G Humbert; J M Lang; P Massip; D Mechali; P Leclercq; J Modai; H Portier
Journal:  AIDS       Date:  1997-10       Impact factor: 4.177

2.  Impact of combination therapy for HIV infection on inpatient census.

Authors:  R A Torres; M Barr
Journal:  N Engl J Med       Date:  1997-05-22       Impact factor: 91.245

3.  The role of combinations of HIV protease inhibitors in the management of persons with HIV infection.

Authors:  G Moyle
Journal:  Expert Opin Investig Drugs       Date:  1998-03       Impact factor: 6.206

4.  Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering Group.

Authors:  E J Beck; S Mandalia; I Williams; A Power; R Newson; A Molesworth; D Barlow; P Easterbrook; M Fisher; J Innes; G Kinghorn; B Mandel; A Pozniak; A Tang; D Tomlinson
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

5.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; M Opravil; A Telenti; B Hirschel; M Battegay; P Vernazza; P Sudre; M Flepp; H Furrer; P Francioli; R Weber
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

6.  Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS.

Authors:  M M Berrey; T Schacker; A C Collier; T Shea; S J Brodie; D Mayers; R Coombs; J Krieger; T W Chun; A Fauci; S G Self; L Corey
Journal:  J Infect Dis       Date:  2001-04-24       Impact factor: 5.226

7.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

8.  The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine.

Authors:  A Mocroft; S Barry; C A Sabin; A C Lepri; S Kinloch; A Drinkwater; M Lipman; M Youle; M A Johnson; A N Phillips
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

9.  A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.

Authors:  J C Lopez Bernaldo de Quiros; J M Miro; J M Peña; D Podzamczer; J C Alberdi; E Martínez; J Cosin; X Claramonte; J Gonzalez; P Domingo; J L Casado; E Ribera
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

10.  The defined daily dose per 100 bed-days as a unit of comparison and a parameter for studying antimicrobial drug use in a university hospital. A retrospective study of the effects of guidelines and audit on antimicrobial drug use.

Authors:  Y A Hekster; T B Vree; R J Goris; J B Boerema
Journal:  J Clin Hosp Pharm       Date:  1982-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.